|

Donafenib Clinical Trials

7 actively recruiting trials

No change since May 2026

Also known as: Zepsun

Pipeline

Phase 2: 3

Top Sponsors

  • Ze-yang Ding, MD1
  • West China Hospital1
  • Tongji Hospital1
  • The First Affiliated Hospital with Nanjing Medical University1
  • Sun Yat-sen University1

Indications

Other7 trials

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
Phase 2
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
N/A
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
N/A
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.